Compare
Roivant Sciences Ltd. vs Tonix Pharmaceuticals Holding Corp. vs ProPhase Labs, Inc. vs CASI Pharmaceuticals, Inc.
| Latest fiscal year | Roivant Sciences Ltd. ROIV | Tonix Pharmaceuticals Holding Corp. TNXP | ProPhase Labs, Inc. PRPH | CASI Pharmaceuticals, Inc. CASIF |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $8.26M | $13.11M | $4.34M | $20.71M |
| Revenue growth (YoY) | -71.6% | +29.8% | -35.8% | -27.4% |
| Gross margin | n/a | 49.3% (computed) | 31.9% | 48.6% |
| Operating margin | n/m | -959.1% | -415.4% | -217.3% |
| Net margin | n/m | -946.2% | -339.3% | -232.0% |
| Net income | -$299.77M | -$124.02M | -$14.74M | -$48.06M |
| EPS (Diluted) | -$0.54 | -$14.57 | -$1.74 | -$2.59 |
| Operating cash flow | -$750.35M | -$99.84M | -$8.34M | -$20.75M |
| Free cash flow | -$758.56M | -$103.21M | -$8.34M | -$20.77M |
| Cash & equivalents | $1.42B | $207.64M | $90.0K | $5.63M |
| Total assets | $5.71B | $277.17M | $59.87M | $25.65M |
| Total liabilities | $416.27M | $32.02M | $56.36M | $62.93M |
| Shareholders' equity | $4.53B | $245.15M | $3.51M | -$37.28M |
| Return on year-end equity | -6.6% | -50.6% | -420.3% | n/a |
| Shares outstanding | 720.35M | 12.79M | 8.97M | 20.56M |
Revenue, most recent five fiscal years
| Fiscal year | Roivant Sciences Ltd. | Tonix Pharmaceuticals Holding Corp. | ProPhase Labs, Inc. | CASI Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $8.26M Ended 2026-03-31 | $13.11M Ended 2025-12-31 | $4.34M Ended 2025-12-31 | $20.71M Ended 2025-12-31 |
| 1 year earlier | $29.05M Ended 2025-03-31 | $10.09M Ended 2024-12-31 | $6.77M Ended 2024-12-31 | $28.54M Ended 2024-12-31 |
| 2 years earlier | $32.71M Ended 2024-03-31 | $7.77M Ended 2023-12-31 | $34.98M Ended 2023-12-31 | $33.88M Ended 2023-12-31 |
| 3 years earlier | $31.53M Ended 2023-03-31 | n/a | $122.65M Ended 2022-12-31 | $43.11M Ended 2022-12-31 |
| 4 years earlier | $55.29M Ended 2022-03-31 | n/a | $79.04M Ended 2021-12-31 | $30.17M Ended 2021-12-31 |